Dr. Dreicer on Future Treatment Approaches in Prostate Cancer

Robert Dreicer, MD
Published Online: Thursday, Feb 16, 2017



Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the progress he would like to see accomplished in the field of metastatic castration-resistant prostate cancer.

It would be a huge step in the field, Dreicer explains, to have AR-V7 assays that are validated and commercially available. Additionally, he hopes to see more prospective data to validate what was previously demonstrated by researchers of Johns Hopkins Medicine with the AR-V7 Prostate Cancer Assay. Although such data were interesting, they were small numbers, and prospective validation from other centers would be useful before all physicians incorporate it into their daily practice.

Dreicer also hopes that, over the next year, the community is able to move some new compounds down the pipeline that may have abilities to overcome some  resistance pathways. Researchers are looking to use the androgen receptor-pathway downstream.


Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the progress he would like to see accomplished in the field of metastatic castration-resistant prostate cancer.

It would be a huge step in the field, Dreicer explains, to have AR-V7 assays that are validated and commercially available. Additionally, he hopes to see more prospective data to validate what was previously demonstrated by researchers of Johns Hopkins Medicine with the AR-V7 Prostate Cancer Assay. Although such data were interesting, they were small numbers, and prospective validation from other centers would be useful before all physicians incorporate it into their daily practice.

Dreicer also hopes that, over the next year, the community is able to move some new compounds down the pipeline that may have abilities to overcome some  resistance pathways. Researchers are looking to use the androgen receptor-pathway downstream.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary MalignanciesMay 27, 20171.5
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Genitourinary CancersJul 28, 20171.5
Publication Bottom Border
Border Publication